• 1
    Heddle N, Cook R, Tinmouth A, et al. A randomized controlled trial comparing standard and low dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009;113:1564-1573.
  • 2
    Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 1997;337:1870-1875.
  • 3
    Tinmouth A, Tannock IF, Crump M, et al. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design. Transfusion 2004;44:1711-1719.
  • 4
    Sensebe L, Giraudeau B, Bardiaux L, et al. The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study. Blood 2005;105:862-864.
  • 5
    Diedrich B, Remberger M, Shanwell A, et al. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 10(9) per L versus 30 x 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion 2005;45:1064-1072.
  • 6
    Heckman KD, Weiner GJ, Davis CS, et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol 1997;15:1143-1149.
  • 7
    Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet transfusion strategy for hematologic cancers. N Engl J Med 2013;368:1771-1780.
  • 8
    Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012;380:1309-1316.
  • 9
    Estcourt LJ, Stanworth SJ, Murphy MF. Platelet transfusions for patients with haematological malignancies: who needs them? Br J Haematol 2011;154:425-440.
  • 10
    Stanworth SJ, Dyer C, Choo L, et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfus Med Rev 2010;24:163-171.
  • 11
    Kahan BC, Morris TM. Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysis. BMJ 2012;345:e5840.
  • 12
    Kahan BC, Morris TP. Improper analysis of trials randomised using stratified blocks or minimisation. Stat Med 2012;31:328-340.
  • 13
    British Committee for Standards in Haematology and Blood Transfusion Task Force (Chairman P. Kelsey). Guidelines for the use of platelet transfusions. Br J Haematol 2003;122:10-23.
  • 14
    Estcourt LJ, Heddle N, Kaufman R, et al. The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Transfusion 2013;53:1531-1543.
  • 15
    Wang R, Lagakos SW, Ware JH, et al. Statistics in medicine—reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-2194.
  • 16
    Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995;311:485.
  • 17
    Sun X, Briel M, Walter SD, et al. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 2010;340:c117.
  • 18
    Schiffer CA. Haematological cancer: prophylactic platelet transfusion is frequently not necessary. Nat Rev Clin Oncol 2013;10:431-432.
  • 19
    Morowski M, Vogtle T, Kraft P, et al. Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice. Blood 2013;121:4938-4947.
  • 20
    Goerge T, Ho-Tin-Noe B, Carbo C, et al. Inflammation induces hemorrhage in thrombocytopenia. Blood 2008;111:4958-4964.
  • 21
    McCullough J, Vesole D, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004;104:1534-1541.
  • 22
    Zumberg MS, del Rosario ML, Nejame CF, et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/μL versus 20,000/μL trigger. Biol Blood Marrow Transplant 2002;8:569-576.
  • 23
    Estcourt LJ. Risk factors of intra-cranial haemorrhage in thrombocytopenic haematology patients: a case-control study. In: ISRCTN Register. 2011 ed: Clinical Trials Register; 2011:ISRCTN05026912.
  • 24
    Williamson LM, Devine DV. Challenges in the management of the blood supply. Lancet 2013;381:1866-1875.
  • 25
    Wardrop D, Estcourt L, Brunskill SJ, et al. Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. Cochrane Database Syst Rev 2013;(7):CD009733.